Frontiers in oncology · 2026
Nomogram-based prediction models for clinical outcomes in pediatric RUNX1::RUNX1T1-positive acute myeloid leukemia: a retrospective analysis from AML-CAMS serial trials.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Xiaoli, Zhang Luyang, Zheng Yangyang, Hu Tianyuan, Yi Meihui, Guo Ye, Chen Xiaojuan, Chen Yumei, Zou Yao, Zhang Li, Yang Wenyu, Zhang Yingchi, Ruan Min, Zhu Xiaofan
Аннотация
OBJECTIVE: To identify prognostic factors and develop nomograms predicting short-term mortality and relapse in pediatric RUNX1::RUNX1T1-positive AML, thereby enabling individualized risk assessment and optimizing clinical management.
METHODS: We retrospectively analyzed 136 pediatric patients with RUNX1::RUNX1T1-positive AML who achieved morphologic complete remission (CR) after one induction course under AML-CAMS-2009 or AML-CAMS-2016 regimen. Least absolute shrinkage and selection operator (LASSO) and multivariable Cox regression identified independent predictors of 3-year overall survival (OS) and relapse-free survival (RFS). Nomograms were built from these predictors. Model performance was assessed by time-dependent receiver operating characteristic (ROC) curves, calibration plots, decision curve analysis (DCA), and concordance index (C-index), with internal validation performed by bootstrap resampling.
RESULTS: High-Risk measurable residual disease (MRD), treatment regimen, and diagnostic white blood cell (WBC) group (≥20×10⁹/L vs. <20×10⁹/L) independently predicted OS. For RFS, independent predictors were percentage of bone marrow blasts by flow cytometry (BM blasts [FCM]), extramedullary infiltration (EMI), High-Risk MRD, treatment regimen, and WBC group. Nomograms demonstrated strong discrimination and calibration with superior clinical net benefit versus any single predictor. Nomogram-derived scores stratified patients into prognostically distinct subgroups with significant differences in OS and RFS.
CONCLUSIONS: This study established internally validated 3-year OS and RFS nomograms for pediatric RUNX1::RUNX1T1-positive AML with excellent discrimination and clinical utility. Prospective multicenter validation is warranted to confirm the robustness and facilitate clinical adoption.
METHODS: We retrospectively analyzed 136 pediatric patients with RUNX1::RUNX1T1-positive AML who achieved morphologic complete remission (CR) after one induction course under AML-CAMS-2009 or AML-CAMS-2016 regimen. Least absolute shrinkage and selection operator (LASSO) and multivariable Cox regression identified independent predictors of 3-year overall survival (OS) and relapse-free survival (RFS). Nomograms were built from these predictors. Model performance was assessed by time-dependent receiver operating characteristic (ROC) curves, calibration plots, decision curve analysis (DCA), and concordance index (C-index), with internal validation performed by bootstrap resampling.
RESULTS: High-Risk measurable residual disease (MRD), treatment regimen, and diagnostic white blood cell (WBC) group (≥20×10⁹/L vs. <20×10⁹/L) independently predicted OS. For RFS, independent predictors were percentage of bone marrow blasts by flow cytometry (BM blasts [FCM]), extramedullary infiltration (EMI), High-Risk MRD, treatment regimen, and WBC group. Nomograms demonstrated strong discrimination and calibration with superior clinical net benefit versus any single predictor. Nomogram-derived scores stratified patients into prognostically distinct subgroups with significant differences in OS and RFS.
CONCLUSIONS: This study established internally validated 3-year OS and RFS nomograms for pediatric RUNX1::RUNX1T1-positive AML with excellent discrimination and clinical utility. Prospective multicenter validation is warranted to confirm the robustness and facilitate clinical adoption.